OrthoPediatrics Corp. KIDS 深 沪
已收盘 02-06 16:00:00 美东时间
16.65
+0.060
+0.36%
华盛通- 最 高16.985
- 今 开16.85
- 成交量 8.00万股
- 最 低 16.455
- 昨 收 16.59
- 总市值 4.18亿
- 52周最高 26.40
- 市盈率 静 --
- 换手率 0.32%
- 52周最低 15.28
- 委 比 51.17%
- 总股本 2507.73万
- 历史最高 73.91
- 量 比 0.64
- 振 幅 3.19%
- 历史最低 14.00
- 每 手 1
- 风险率 2.59%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多OrthoPediatrics Announces Expanded Enabling Technology Market Opportunity
OrthoPediatrics partner iotaMotion receives FDA clearance for expanded use of its iotaSOFT® cochlear implant insertion system in patients four years and older. The system, designed to enhance cochlear implant surgery by controlling electrode insertion speed and consistency, is now available for school-aged children. Cincinnati Children’s Hospital becomes the first dedicated pediatric center to adopt the technology, which is already used by over 3...
02-03 12:05
美股大行评级 | 瑞穗上调希捷科技、西部数据、CoreWeave目标价；Trade Desk、W.R. Berkley遭多家大行下调目标价
今日重点评级关注：瑞穗：维持Syndax制药"跑赢大市"评级，目标价从410美元升至600美元；HC Wainwright & Co.：维持60 Degrees Pharmaceuticals, Inc."买入"评级，目标价从6美元升至24美元
01-28 10:59
TD Cowen Initiates Coverage On OrthoPediatrics with Buy Rating, Announces Price Target of $23
TD Cowen analyst Mathew Blackman initiates coverage on OrthoPediatrics (NASDAQ:KIDS) with a Buy rating and announces Price Target of $23.
01-27 21:48
OrthoPediatrics sees FY25 revenue of $236.1M
OrthoPediatrics (KIDS) on Monday said posted record preliminary unaudited full year 2025 net revenue of $236.1 million, representing continued growth compared to $204.7 million in 2024 of 15%. Prelimi...
01-12 20:50
OrthoPediatrics Raises FY2025 Sales Guidance from $233.500M-$234.500M to $236.100M vs $234.002M Est
OrthoPediatrics (NASDAQ:KIDS) raises FY2025 sales outlook from $233.500 million-$234.500 million to $236.100 million vs $234.002 million estimate.
01-12 20:08
快讯 | OrthoPediatrics Corp. 创下2025年全年未经审计初步收入记录，并发布2026年财务指引
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Ye...
01-12 20:05
OrthoPediatrics Corp. Achieves Record Preliminary Unaudited Revenue for Full Year 2025 and Issues 2026 Financial Guidance
OrthoPediatrics Corp. reported a record full year 2025 revenue of $236.1 million, a 15% increase from 2024. Fourth quarter 2025 revenue was $61.3 million, up 16% year-over-year. The company helped over 37,500 children in Q4 2025, reaching nearly 1.3 million since inception. OrthoPediatrics expects 2026 revenue of $262-$266 million, representing 11%-13% growth, and aims for $25 million Adjusted EBITDA.
01-12 12:05
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
2025-12-11 10:33
Canaccord Genuity Initiates Coverage On OrthoPediatrics with Buy Rating, Announces Price Target of $24
Canaccord Genuity analyst Caitlin Roberts initiates coverage on OrthoPediatrics (NASDAQ:KIDS) with a Buy rating and announces Price Target of $24.
2025-12-10 21:01
OrthoPediatrics Corp. Expands Specialty Bracing Portfolio with Two New Product Launches
OrthoPediatrics Corp. announced the expansion of its OrthoPediatrics Specialty Bracing (OPSB) portfolio with two new products, the PediHip™ Rigid Brace and PediHip™ Modular Abduction Systems, now totaling 31 systems. These products are designed for the treatment of Developmental Dysplasia of the Hip (DDH) and post-operative stabilization in pediatric patients aged three years and younger. Joe Hauser, President of the OPSB division, highlighted th...
2025-11-13 12:00
